Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma

NCT05209620 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05209620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05209620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 21, 2021
Completion date
December 21, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma